Recent reports provide evidence for a role of SLITRK1 in Tourette's syndrome (TS) with obsessive-compulsive (OC) symptoms and for the G56A serotonin transporter gene (SLC6A4) variant in autism.
1,2 Here, we investigated these gene variants in obsessivecompulsive disorder (OCD), based on high degrees of TS/OCD comorbidity, plus G56A functionally resembling SLC6A4 I425 V in producing transporter gain-offunction. [2] [3] [4] SLITRK1 was uncovered as a candidate for TS owing to its < 230 kb proximity to a breakpoint of a 13q chromosomal inversion found in a child with TS and attention-deficit/hyperactivity disorder (ADHD), in addition to its role in neurite outgrowth. 1 Furthermore, screening of 174 additional TS probands for SLITRK1 variants revealed a truncating frameshift mutation, varCDfs, with complete loss of function in one, and a microRNA domain-affecting variant, var321, which leads to reduced reporter gene activity in vitro, in two other of these probands (Table 1) . 1 Because B40% of TS probands have OCD or at least moderate obsessive-compulsive symptoms, 5 and because of the specific overlap of tics, TS and OC symptoms in the four families with 13q and SLITRK1 anomalies and variants, 1 we performed a case-control association study and genotyped 322 OCD probands and 390 controls for SLITRK1 var321 and varCDfs. The probands met DSM-IV criteria for OCD and were comprised of 156 female and 123 male subjects of Caucasian ethnicity as well as 25 female and 18 male subjects of other ethnicities (details in the legend of Table 2 ). The sample demographics thus were similar to previous studies of SLITRK1 and G56A. 1, 2, 6 A total of 13% had one or more first-degree relatives affected with OCD, which is in accordance with previously reported frequencies. 7 Further details including rates of comorbidities have been reported elsewhere. MO, USA). As these two groups were not clinically evaluated, we cannot rule out the possibility of individuals present in the control sample with OCD or OC symptoms, although this fraction is unlikely to be higher than the general population prevalence of 2-3%. 7 Genotyping was performed by 5 0 -exonuclease assays (TaqMan assay-by-design, Applied Biosystems, Foster City, CA, USA); primer and probe sequences are listed in Table 1 . Overall genotype completion rate was greater than 98%; a total of 15% of all samples were run in duplicate and revealed no discrepancies. All detected Ala56 (see below) and var321 alleles were confirmed by bidirectional dideoxy sequencing at the NINDS DNA Sequencing Facility. Amplified genomic DNA of SLITRK1 var321 and varCDfs heterozygotes (kindly provided by Dr M State, Yale University) served as positive controls. Contingency table statistics were calculated with the software GraphPad Prism version 4 (San Diego, CA, USA). Table 2 (top) summarizes absolute genotype frequencies for SLITRK1 variants. We did not observe any of the rare SLITRK1 variants in our OCD probands. This raises the possibility that SLITRK1 is more closely associated with the tics and ADHD phenotype components of TS rather than the OC component.
Remarkably, however, we detected one var321 heterozygote female subject in the US Caucasian controls (Coriell NA18062). Also of note, this same individual carried the very rare ( < 1%) S G allele of the SLC6A4 transcriptional control polymorphism, 5-HTTLPR. 9 As no further phenotypic information was available from the cell repository when we contacted them, we cannot evaluate nor rule out the possibility of subclinical neuropsychiatric symptomatology in this person.
Abelson et al. 1 did not observe SLITRK1 var321 in 4296 control chromosomes in primarily Caucasian and African-American ethnicities. With the var321 variant discovered here being only the fourth confirmed allele besides the two TS probands and one family member, further analyses in even larger populations are warranted.
Dysfunction of central serotonergic neurotransmission has been implicated in the etiology of OCD based on the efficacy of serotonin reuptake inhibitors in its pharmacological treatment. 10 From a genetic perspective, this theory is supported by the recently identified gain-of-function point mutation I425 V of SLC6A4, which was initially associated with a complex, primarily OCD-like phenotype in six of seven family members of two unrelated families carrying the mutation 3 and subsequently observed segregating in three more families with OCD.
11
Another rare coding SLC6A4 variant, G56A, has recently been suggested to confer susceptibility to autism with predominantly rigid-compulsive symptomatology in an autism multiplex family study that also demonstrated a strong linkage analysis peak near the SLC6A4 gene for male, but not for female, probands.
2 Both the I425 V and the G56A variants have been shown to lead to an increased serotonin transporter protein activity in transfected cell lines. [2] [3] [4] In the same population of our 322 OCD probands and 390 controls, allelic frequencies for G56A (Table 2) did not differ significantly between probands and controls and are in agreement with previous reports. 2, 12 We identified one Ala56 homozygote in the US Caucasian control population (Coriell NA17267); all other Ala56 alleles occurred as heterozygotes.
Thus, our data provide no support for a role of any of the three functional variants, SLC6A4 G56A or In addition to the 279 Caucasian OCD probands shown here, we genotyped 10 African American (7f, 3m), four Asian (3f, 1m), eight Latin American (3f, 5m) and 21 (12f, 9m) OCD probands of other ethnicities, all of which were homozygous for the SLC6A4 Gly56 allele and for both SLITRK1 wild-type alleles. a Caucasian probands only and combined US and UK Caucasian controls; MAF, minor allele frequency (Ala56). The allelic frequency for Ala56 presented here is in agreement with linkage analysis data by Sutcliffe et al. 2 (1.1 and 2.3% MAF for multiplex autism families with low and high logarithm of the odds scores near the SLC6A4 locus, respectively) and somewhat higher than the study by Glatt et al. 12 (MAF 0.44%). The latter difference might reflect methodological differences in the sensitivity of denaturing HPLC employed by Glatt et al. 12 compared to probe-based detection chemistry used here and by Sutcliffe et al.
SLITRK1 var321 or varCDfs, as candidate loci for OCD. They somewhat reduce the probability of SLITRK1 var321 being associated exclusively with TS. Rare genetic alterations can be very useful in the identification of potential pathophysiological mechanisms of diseases. 13 However, continued caution and collaborative investigations using very large samples will continue to be necessary before the role of rare variants such as these in common complex disorders such as OCD and TS will be understood.
